2208-15-3

Usage

Uses

Used in Pharmaceutical Research:
4-bromo-3-hydroxy-2-naphthoic acid is used as a potential candidate for the development of new drugs due to its unique chemical properties and pharmacological potential.
Used in Organic Synthesis:
4-bromo-3-hydroxy-2-naphthoic acid is used as a building block in the synthesis of more complex organic molecules, contributing to the creation of novel compounds with specific applications.
Used in Anti-inflammatory Applications:
4-bromo-3-hydroxy-2-naphthoic acid is used as an anti-inflammatory agent, leveraging its pharmacological properties to modulate inflammatory responses and alleviate associated symptoms.
Used in Antioxidant Applications:
4-bromo-3-hydroxy-2-naphthoic acid is used as an antioxidant, protecting cells from oxidative stress and potentially reducing the risk of various diseases associated with oxidative damage.
Used in Dye and Fluorescent Whitening Agent Manufacturing:
Although 4-bromo-3-hydroxy-2-naphthoic acid itself is not directly used in this industry, its parent compound, 2-naphthoic acid, is utilized in the production of dyes and fluorescent whitening agents. The unique properties of 4-bromo-3-hydroxy-2-naphthoic acid may also contribute to the development of new dyes or whitening agents with improved characteristics.

InChI:InChI=1/C11H7BrO3/c12-9-7-4-2-1-3-6(7)5-8(10(9)13)11(14)15/h1-5,13H,(H,14,15)

Upstream product

• 92-70-6 3-Hydroxy-2-naphthoic acid 
• 7732-18-5 water 
• 7726-95-6 bromine 
• 67097-82-9 sodium 3-hydroxy-4-sulphonato-2-naphthoic acid 
• 124-38-9 carbon dioxide 
• 30478-89-8 1,3-dibromonaphthalen-2-ol 

Downstream Products

• 88-99-3 benzene-1,2-dicarboxylic acid 
• 170889-47-1 diphenyl 2,2'-dihydroxy-[1,1'-binaphthalene]-3,3'-dicarboxylate 
• 1451072-11-9 C₂₆H₂₁ClO₂ 
• 1451072-10-8 methyl 4-(4-methoxyphenyl)-3-(p-tolyl)-2-naphthoate 
• 1451072-09-5 C₂₆H₁₉F₃O₂ 
• 1451072-08-4 C₁₈H₁₂BrClO₂ 
• 1451072-07-3 C₁₈H₁₂BrFO₂ 
• 1451072-06-2 C₁₉H₁₅BrO₂ 
• 1451072-05-1 C₁₉H₁₅BrO₂ 
• 1451072-04-0 C₂₀H₁₇BrO₂ 
• 1451072-03-9 methyl 4-bromo-3-(4-methoxyphenyl)-2-naphthoate 
• 1451072-02-8 C₂₆H₁₆F₆O₂ 

Relevant academic research and scientific papers

Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity

To continue our study of 2-morpholino-benzoxazine based compounds, which show useful activity against PI3K family enzymes or antiplatelet activity, we designed and synthesized a series of linear 6.7-fused, 5,6-angular fused and 7,8-angular fused-aryl-morpholino-naphth-oxazines. The compounds were prepared from substituted 2-hydroxynaphthoic acid to give the corresponding thioxo analogues 8, 9, 15 and 19. The thioxo products were then converted to the morpholino substituted analogue. The aryl group was introduced by Suzuki coupling of bromo precursors. The products were evaluated for activity at PI3K family enzymes and as platelet aggregation inhibitors and compared to reported unsubstituted analogues. The linear 6.7-fused product 13a and 13b were moderated potent but selective PI3Kδ isoform inhibitors (IC50?=?7.7 and 5.61?μM). Good antiplatelet activity was noticed for the angular 7,8-fused compounds 22a, b, k and l with IC50?=?3.0,14.0, 2.0 and 5.0?μM respectively. The antiplatelet activity is independent of PDE3.

Construction of Axially Chiral Arylborons via Atroposelective Miyaura Borylation

Compared with the well-developed centrally chiral boron chemistry, C-B axially chiral chemistry remains elusive and challenging. Herein we report the first atroposelective Miyaura borylation of bromoarenes with unsymmetrical diboron reagents for the direct catalytic synthesis of optically active atropisomeric arylborons. This reaction features broad substrate scope and produces axially chiral arylborons with high yields and good enantioselectivities.

Nickel-Catalyzed Directed Cross-Electrophile Coupling of Phenolic Esters with Alkyl Bromides

Herein, we demonstrate the successful use of robust phenolic esters as an electrophilic acyl source in the reaction with diverse primary and secondary unactivated alkyl bromides. The cleavage of the relatively inert C-O bond is facilitated by the neighboring coordinating hydroxyl or sulfonamide moiety. By circumventing the use of pregenerated organometallics, this method allows efficient preparation of a variety of o-hydroxyl and tosyl-protected o-amino aryl ketones with high compatibility with a wide range of functionalities.

PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND

Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes.

PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN

Novel preparations comprising ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer wherein the ligand is extended by protamine that are capable of prolonging the ac-tion of insulin preparations.

Stabilised insulin compositions

The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The resulting preparations have improved physical and chemical stability.

Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer

Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

Modifier composition for azo pigments based on 2-hydroxy-3-naphthoic acid

The use of alpha-substituted-2-hydroxy-3-naphthoic acids to replace part of the conventional 2-hydroxy-3-naphthoic acid coupling component results in improved azo dyes.